378 related articles for article (PubMed ID: 34297329)
1. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
3. When can we stop nucleoside analogues in patients with chronic hepatitis B?
Chong CH; Lim SG
Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
[TBL] [Abstract][Full Text] [Related]
4. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
[TBL] [Abstract][Full Text] [Related]
5. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review.
Liu J; Li T; Zhang L; Xu A
Hepatology; 2019 Sep; 70(3):1045-1055. PubMed ID: 30561829
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.
Tout I; Lampertico P; Berg T; Asselah T
Antiviral Res; 2021 Jan; 185():104992. PubMed ID: 33279523
[TBL] [Abstract][Full Text] [Related]
8. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
10. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
11. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations].
Martín Mateos RM; Moreira Vicente VF; Tavío Hernández E; Cuño Roldán JL; Téllez Villajos L; Aicart Ramos M; Arribas Anta J; Zaera de la Fuente C; Albillos Martínez A
Gastroenterol Hepatol; 2015 May; 38(5):305-12. PubMed ID: 25636371
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
Hall SAL; Vogrin S; Wawryk O; Burns GS; Visvanathan K; Sundararajan V; Thompson A
Gut; 2022 Aug; 71(8):1629-1641. PubMed ID: 34493592
[TBL] [Abstract][Full Text] [Related]
13. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
15. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
[TBL] [Abstract][Full Text] [Related]
17. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
van Bömmel F; Berg T
Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Chang ML; Liaw YF; Hadziyannis SJ
Aliment Pharmacol Ther; 2015 Aug; 42(3):243-57. PubMed ID: 26151841
[TBL] [Abstract][Full Text] [Related]
20. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]